Literature DB >> 28538743

Pathophysiology of hidradenitis suppurativa.

Lauren K Hoffman1, Mondana H Ghias2, Michelle A Lowes3.   

Abstract

The pathophysiology of hidradenitis suppurativa (HS) is not well understood. Some of our knowledge comes from clinical and epidemiological observations, along with studies of the histopathology and immunohistochemistry of affected skin. More recently, cutaneous molecular studies and transcriptomic analyses have provided additional information regarding inflammatory processes. The chronic cutaneous inflammation, systemic symptoms, and associated comorbidities suggest that HS should be classified as an immune-mediated disease, rather than a primary infectious disease. As such, a proposed integrated disease pathway is presented. At a fundamental level, there appears to be a primary abnormality in the pilosebaceous-apocrine unit, which leads to follicular occlusion, perifollicular cyst development that traps commensal microbes, and rupture into the dermis. This can trigger an exaggerated response of the cutaneous innate immune system. Initially this is an acute event, but ongoing intermittent disease activity can lead to recurrent inflammatory nodules and dermal tunnels. Once underway, the cutaneous inflammation is very difficult to turn off, leading to suppurative inflammation in whole anatomic regions. As the disease progresses, we propose that there is recruitment of the systemic immune system perpetuating the chronic cutaneous inflammatory process. There remains much to be done to understand the pathogenesis and immune signature of this challenging disease. ©2017 Frontline Medical Communications.

Entities:  

Keywords:  apocrine glands; cutaneous inflammation; hidradenitis suppurativa; systemic immune system

Mesh:

Year:  2017        PMID: 28538743     DOI: 10.12788/j.sder.2017.017

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  15 in total

1.  Proceeding report of the third symposium on Hidradenitis Suppurativa advances (SHSA) 2018.

Authors:  Claudia J Posso-De Los Rios; Akua Sarfo; Mondana Ghias; Raed Alhusayen; Iltefat Hamzavi; Michelle A Lowes; Afsaneh Alavi
Journal:  Exp Dermatol       Date:  2019-04-29       Impact factor: 3.960

2.  Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017.

Authors:  Eran Shavit; Afsaneh Alavi; Falk G Bechara; Richard G Bennett; Marc Bourcier; Ricardo Cibotti; Steven Daveluy; John W Frew; Amit Garg; Iltefat Hamzavi; Lauren K Hoffman; Jenny Hsaio; Joslyn Sciacca Kirby; Hadar Lev-Tov; Erin Martinez; Robert Micheletti; Haley B Naik; Aude Nassif; Cynthia Nicholson; Angie Parks-Miller; Zarine Patel; Vincent Piguet; Mayur Ramesh; Barry Resnik; Christopher Sayed; Gregory Schultz; Aamir Siddiqui; Jerry Tan; Ximena Wortsman; Michelle A Lowes
Journal:  Exp Dermatol       Date:  2019-01       Impact factor: 3.960

Review 3.  Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017.

Authors:  Haley B Naik; Aude Nassif; Mayur S Ramesh; Gregory Schultz; Vincent Piguet; Afsaneh Alavi; Michelle A Lowes
Journal:  J Invest Dermatol       Date:  2018-11-08       Impact factor: 8.551

4.  Dynamic Leukocyte Populations Are Associated With Early- and Late-stage Lesions in Hidradenitis Suppurativa.

Authors:  Savanna R Altman; Sheila L Criswell
Journal:  J Histochem Cytochem       Date:  2020-11-26       Impact factor: 2.479

Review 5.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

Review 6.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

7.  Pain in Hidradenitis Suppurativa: A Cross-sectional Study of 1,795 Patients.

Authors:  Piotr K Krajewski; Łukasz Matusiak; Esther von Stebut; Michael Schultheis; Uwe Kirschner; Georgios Nikolakis; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2021-01-05       Impact factor: 3.875

8.  Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature.

Authors:  Lauren K Hoffman; Lewis E Tomalin; Gregory Schultz; Michael D Howell; Niroshana Anandasabapathy; Afsaneh Alavi; Mayte Suárez-Fariñas; Michelle A Lowes
Journal:  PLoS One       Date:  2018-09-28       Impact factor: 3.240

Review 9.  Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.

Authors:  John W Frew; Jason E Hawkes; James G Krueger
Journal:  Ther Adv Chronic Dis       Date:  2019-03-01       Impact factor: 5.091

10.  The skin transcriptome in hidradenitis suppurativa uncovers an antimicrobial and sweat gland gene signature which has distinct overlap with wounded skin.

Authors:  Margaret Coates; Paula Mariottoni; David L Corcoran; Hélène Fradin Kirshner; Tarannum Jaleel; David A Brown; Stephen R Brooks; John Murray; Maria I Morasso; Amanda S MacLeod
Journal:  PLoS One       Date:  2019-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.